Effects of Human Aging on Patterns of Local Cerebral Glucose Utilization Determined by the [18F]fluorodeoxyglucose Method
Overview
Endocrinology
Neurology
Authors
Affiliations
The [18F]fluorodeoxyglucose (FDG) scan method with positron emission computed tomography was used to determine patterns of local cerebral glucose utilization (LCMRglu) in 40 normal volunteer subjects aged 18 to 78 years. Throughout all the studies, each subject was quiet, without movement, with eyes open and ears unplugged, exposed only to ambient room light and sound. For the entire group, whole brain mean CMRglu was 26.1 +/- 6.1 mumol 100 g-1 min-1 (mean +/- SD, n = 40). At age 78, mean CMRglu was, on the average, 26% less than at age 18, an alteration of the same order as the variance among subjects at any age. The gradual decline of mean CMRglu with advancing age occurred at a faster rate than was reported for mean cerebral oxygen utilization, possibly due to increasingly altered pathways for glucose utilization, or to increasing oxidation of ketone bodies or other alternative substrates. Glucose utilization in the hemispheres was symmetrical and mean CMRglu of overall cortex, caudate, and thalamus was equal in individuals at all ages. The slopes of decline with age were similar when LCMRglu was averaged over zones corresponding to centrum semiovale, caudate, putamen, and frontal, temporal, parietal, occipital, and primary visual cortex. However, the metabolic ratio of superior frontal cortex to superior parietal cortex declined with age, possibly due to selective degeneration of superior frontal cortex or to differences between age groups in the sensory and cognitive response to the study. These results should be useful in distinguishing age from disease effects when the FDG scan method is used.
Quantitative PET imaging and modeling of molecular blood-brain barrier permeability.
Chung K, Abdelhafez Y, Spencer B, Jones T, Tran Q, Nardo L medRxiv. 2024; .
PMID: 39108503 PMC: 11302722. DOI: 10.1101/2024.07.26.24311027.
Kojima K, Ishikawa H, Watanabe S, Nosaka N, Mutoh T Nutrients. 2023; 15(14).
PMID: 37513691 PMC: 10383836. DOI: 10.3390/nu15143275.
Deery H, Di Paolo R, Moran C, Egan G, Jamadar S Hum Brain Mapp. 2022; 44(3):1251-1277.
PMID: 36269148 PMC: 9875940. DOI: 10.1002/hbm.26119.
Deery H, Di Paolo R, Moran C, Egan G, Jamadar S Psychophysiology. 2022; 60(1):e14159.
PMID: 36106762 PMC: 10909558. DOI: 10.1111/psyp.14159.
Reassessment of Pioglitazone for Alzheimer's Disease.
Saunders A, Burns D, Gottschalk W Front Neurosci. 2021; 15:666958.
PMID: 34220427 PMC: 8243371. DOI: 10.3389/fnins.2021.666958.